Steve Bernitz has taken the role of general partner at Cambridge-based Extera Partners, a life sciences-focused firm specializing in partnerships, acquisitions and new product commercialization.

Bernitz previously served as chief business officer at small molecule drug maker Concert Pharmaceuticals Inc., where he led the company’s $1 billion partnership with GlaxoSmithKline. According to the Extera website, he has also worked as CEO of clinical stage cell therapy firm Histogenics Corp., senior vice president of business and commercial development at Coley Pharmaceutical Group Inc., a vaccine adjuvant technology developer that was bought by Pfizer Inc., and CEO of Organogenesis Inc., a maker of skin treatment products.

Before moving to life sciences, Bernitz held positions in private equity and as a consultant. He earned an MBA from Northwestern University and a bachelor’s degree from Tufts University.

Extera Partners maintains its U.S. office in Cambridge and its European office in Hall, Germany. The firm brings together a network of advisors from such industries as pharmaceuticals, imaging, medical devices and diagnostics.